Egetis Therapeutics Ab Stock Cash Flow From Operations
| EGTX Stock | SEK 3.60 0.20 5.26% |
Egetis Therapeutics AB fundamentals help investors to digest information that contributes to Egetis Therapeutics' financial success or failures. It also enables traders to predict the movement of Egetis Stock. The fundamental analysis module provides a way to measure Egetis Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Egetis Therapeutics stock.
Egetis |
Egetis Therapeutics AB Company Cash Flow From Operations Analysis
Egetis Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Egetis Therapeutics Cash Flow From Operations | (130.11 M) |
Most of Egetis Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Egetis Therapeutics AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Egetis Therapeutics AB has (130.11 Million) in Cash Flow From Operations. This is 124.68% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The cash flow from operations for all Sweden stocks is 113.4% higher than that of the company.
Egetis Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Egetis Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Egetis Therapeutics could also be used in its relative valuation, which is a method of valuing Egetis Therapeutics by comparing valuation metrics of similar companies.Egetis Therapeutics is currently under evaluation in cash flow from operations category among its peers.
Egetis Fundamentals
| Return On Equity | -0.26 | |||
| Return On Asset | -0.14 | |||
| Operating Margin | (7.54) % | |||
| Current Valuation | 698.73 M | |||
| Shares Outstanding | 249.59 M | |||
| Shares Owned By Insiders | 52.07 % | |||
| Shares Owned By Institutions | 14.16 % | |||
| Price To Book | 1.52 X | |||
| Price To Sales | 42.39 X | |||
| Revenue | 38.24 M | |||
| Gross Profit | (58.28 M) | |||
| EBITDA | (101.9 M) | |||
| Net Income | (104.54 M) | |||
| Cash And Equivalents | 207.41 M | |||
| Cash Per Share | 1.26 X | |||
| Total Debt | 4.88 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 3.54 X | |||
| Book Value Per Share | 2.71 X | |||
| Cash Flow From Operations | (130.11 M) | |||
| Earnings Per Share | (0.70) X | |||
| Target Price | 16.2 | |||
| Number Of Employees | 17 | |||
| Beta | 1.07 | |||
| Market Capitalization | 1.51 B | |||
| Total Asset | 569.27 M | |||
| Net Asset | 569.27 M |
About Egetis Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Egetis Therapeutics AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Egetis Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Egetis Therapeutics AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Egetis Stock Analysis
When running Egetis Therapeutics' price analysis, check to measure Egetis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Egetis Therapeutics is operating at the current time. Most of Egetis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Egetis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Egetis Therapeutics' price. Additionally, you may evaluate how the addition of Egetis Therapeutics to your portfolios can decrease your overall portfolio volatility.